We are single-minded in our pursuit of a cure for Glioblastoma Multiforme (GBM), and invite you to explore our Investor Relations page to understand the financial promise that aligns with our life-changing mission.
Quarterlies
View All Financial FilingsNew Releases
View AllCNS Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
04 September, 2024CNS Pharmaceuticals to Participate in at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
27 August, 2024Events
View AllCNS Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
BioMedWire Podcast
LIVE! with Webull Corporate Connect: Biotech Investment Webinar
Your email alerts were set.
The following alerts could not be set:
Resources
Analyst Coverage
CNS Pharmaceuticals, Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding CNS Pharmaceuticals, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of CNS Pharmaceuticals, Inc. or its management. CNS Pharmaceuticals, Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.
Company
CNS Pharmaceuticals a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system malignancies. The Company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.
Additionally, the Company is advancing the development of its WP1244 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500x more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is evaluating the use of WP1244 in the treatment of brain cancers, pancreatic, ovarian, and lymphomas.